FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2739906408> ?p ?o ?g. }

• W2739906408 abstract "Regorafenib is a small molecule inhibitor of multiple transmembrane and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, metastasis, and tumor immunity. Regorafenib is approved for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy or with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Recently an overall survival benefit has been shown in patients with hepatocellular carcinoma (HCC) who had previously been treated with sorafenib (RESORCE). OncoTrack is an Innovative Medicines Initiative (IMI) sponsored project with the goal to improve the basis for identification of biomarkers based on the mechanisms of action of therapies approved for this indication. For this purpose, a panel of CRC-PDX xenografts was generated by the OncoTrack project. At the time of the analysis reported here fifty xenografts had been treated with regorafenib at a dose of 10 mg/kg/d or with vehicle for 24 days. The analysis of tumor growth rates (TGR) showed pronounced differences between different tumors and between vehicle and regorafenib treated models. The relative antitumor activity (relative TGR) of regorafenib varied between -0,13 (good response) and 0.0 (no response). Investigations of relative TGR in relationship to (non-) clinical parameters of the primary tumor such as age, gender, sidedness and tumor histology identified a marginally significant (p= 0.04) better response in tumors from younger patients. No other correlations were detected to this end, which may be due to the small sample number. To correlate antitumor activity of regorafenib with gene expression, RNA was isolated from sections of selected vehicle and regorafenib treated xenografts and hybrized on Affymetrix HuGene-2.1_st human transcriptome arrays. Expression profiles were subsequently analyzed using the Random Forests algorithm to identify gene expression signatures predicting response to regorafenib. The best signatures did not perform better than signatures derived after randomizing responses, i.e. no predictive signature could be identified. Further studies with larger samples sizes are necessary to improve the outcome of such an approach; however one should acknowledge that to date no predictive gene signatures could be identified for multikinase inhibitors, which may be intrinsic to their complex mechanism of action. The research reported here received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement 115234 (OncoTrack). Citation Format: Henrik Seidel, Jens Hoffmann, Ralf Lesche, Sylvia Grunewald, David Henderson, Dieter Zopf. Correlation of preclinical antitumor activity of regorafenib in CRC-PDX xenografts with gene expression and clinical parameters of the primary tumor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5036. doi:10.1158/1538-7445.AM2017-5036" @default.
• W2739906408 created "2017-08-08" @default.
• W2739906408 creator A5002682008 @default.
• W2739906408 creator A5003451608 @default.
• W2739906408 creator A5009242861 @default.
• W2739906408 creator A5015632097 @default.
• W2739906408 creator A5034373024 @default.
• W2739906408 creator A5078695242 @default.
• W2739906408 date "2017-07-01" @default.
• W2739906408 modified "2023-09-25" @default.
• W2739906408 title "Abstract 5036: Correlation of preclinical antitumor activity of regorafenib in CRC-PDX xenografts with gene expression and clinical parameters of the primary tumor" @default.
• W2739906408 doi "https://doi.org/10.1158/1538-7445.am2017-5036" @default.
• W2739906408 hasPublicationYear "2017" @default.
• W2739906408 type Work @default.
• W2739906408 sameAs 2739906408 @default.
• W2739906408 citedByCount "0" @default.
• W2739906408 crossrefType "proceedings-article" @default.
• W2739906408 hasAuthorship W2739906408A5002682008 @default.
• W2739906408 hasAuthorship W2739906408A5003451608 @default.
• W2739906408 hasAuthorship W2739906408A5009242861 @default.
• W2739906408 hasAuthorship W2739906408A5015632097 @default.
• W2739906408 hasAuthorship W2739906408A5034373024 @default.
• W2739906408 hasAuthorship W2739906408A5078695242 @default.
• W2739906408 hasConcept C121608353 @default.
• W2739906408 hasConcept C126322002 @default.
• W2739906408 hasConcept C143998085 @default.
• W2739906408 hasConcept C2776248978 @default.
• W2739906408 hasConcept C2778019345 @default.
• W2739906408 hasConcept C2778695046 @default.
• W2739906408 hasConcept C2779013556 @default.
• W2739906408 hasConcept C2779490328 @default.
• W2739906408 hasConcept C2780259306 @default.
• W2739906408 hasConcept C2780962732 @default.
• W2739906408 hasConcept C502942594 @default.
• W2739906408 hasConcept C526805850 @default.
• W2739906408 hasConcept C71924100 @default.
• W2739906408 hasConceptScore W2739906408C121608353 @default.
• W2739906408 hasConceptScore W2739906408C126322002 @default.
• W2739906408 hasConceptScore W2739906408C143998085 @default.
• W2739906408 hasConceptScore W2739906408C2776248978 @default.
• W2739906408 hasConceptScore W2739906408C2778019345 @default.
• W2739906408 hasConceptScore W2739906408C2778695046 @default.
• W2739906408 hasConceptScore W2739906408C2779013556 @default.
• W2739906408 hasConceptScore W2739906408C2779490328 @default.
• W2739906408 hasConceptScore W2739906408C2780259306 @default.
• W2739906408 hasConceptScore W2739906408C2780962732 @default.
• W2739906408 hasConceptScore W2739906408C502942594 @default.
• W2739906408 hasConceptScore W2739906408C526805850 @default.
• W2739906408 hasConceptScore W2739906408C71924100 @default.
• W2739906408 hasLocation W27399064081 @default.
• W2739906408 hasOpenAccess W2739906408 @default.
• W2739906408 hasPrimaryLocation W27399064081 @default.
• W2739906408 hasRelatedWork W1604441233 @default.
• W2739906408 hasRelatedWork W1965505719 @default.
• W2739906408 hasRelatedWork W1986292340 @default.
• W2739906408 hasRelatedWork W2012258551 @default.
• W2739906408 hasRelatedWork W2013990257 @default.
• W2739906408 hasRelatedWork W2029536410 @default.
• W2739906408 hasRelatedWork W2089310800 @default.
• W2739906408 hasRelatedWork W2090155457 @default.
• W2739906408 hasRelatedWork W2313998349 @default.
• W2739906408 hasRelatedWork W2315517369 @default.
• W2739906408 hasRelatedWork W2321130406 @default.
• W2739906408 hasRelatedWork W2329902813 @default.
• W2739906408 hasRelatedWork W2484891052 @default.
• W2739906408 hasRelatedWork W2493813435 @default.
• W2739906408 hasRelatedWork W2741078763 @default.
• W2739906408 hasRelatedWork W2767475318 @default.
• W2739906408 hasRelatedWork W2787302911 @default.
• W2739906408 hasRelatedWork W2887166320 @default.
• W2739906408 hasRelatedWork W2940964174 @default.
• W2739906408 hasRelatedWork W3214326996 @default.
• W2739906408 isParatext "false" @default.
• W2739906408 isRetracted "false" @default.
• W2739906408 magId "2739906408" @default.
• W2739906408 workType "article" @default.